0
0.5
1
1.5
2+
Mortality, both age groups..
56%
Improvement
Relative Risk
Mortality, age 65+
79%
Mortality, age 40-64
-32%
Hospitalization, both age..
57%
Hospitalization, age 65+
73%
Hospitalization, age 40-64
26%
Paxlovid for COVID-19 Arbel et al. EARLY TREATMENT
Is early treatment with paxlovid beneficial for COVID-19?
Retrospective 109,213 patients in Israel
Lower mortality (p=0.37) and hospitalization (p=0.098), not sig.
c19early.org
Arbel et al., New England J. Medicine, Jun 2022
Favors paxlovid
Favors control